Showing results (1-10 of 1,216) with videos related to
Sort By:
Pageof 122
Trends in Neurosciences|May 4, 2005
Emerging properties of cannabinoid medicines in management of multiple sclerosisGareth Pryce, David BakerBritish Journal of Pharmacology|August 12, 2017
Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in miceGareth Pryce, David BakerCurrent Pharmaceutical Design|September 11, 2008
The endocannabinoid system and multiple sclerosisDavid Baker, Gareth PryceMultiple Sclerosis and Related Disorders|August 3, 2018
Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter?Gareth Pryce, David BakerExpert Opinion on Investigational Drugs|April 1, 2003
The therapeutic potential of cannabis in multiple sclerosisDavid Baker, Gareth PryceHandbook of Experimental Pharmacology|September 27, 2015
Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral SclerosisGareth Pryce, David BakerCNS & Neurological Disorders Drug Targets|May 16, 2012
Potential control of multiple sclerosis by cannabis and the endocannabinoid systemGareth Pryce, David BakerNeuroscience Letters|April 11, 2003
Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in miceGareth Pryce, Gavin Giovannoni, David BakerMultiple Sclerosis and Related Disorders|February 21, 2019
Potential mechanisms of action related to the efficacy and safety of cladribineDavid Baker, Gareth Pryce, Samuel S Herrod, et al.Brain Research|July 11, 2006
Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis miceAna Cabranes, Gareth Pryce, David Baker, et al.Pageof 122